MC4R and Genetic obesity: Setmelanotide (Imcivree) (32), an MC4R agonist marketed to treat certain forms of genetic obesity, resulted in similar responses with the combination of liraglutide (Figure 4, E–H), illustrating the idea that multiple MC4R agonists can increase the effect of liraglutide in inhibiting food intake and weight loss.